Safety profiles of induction therapy with VD or vtD
| . | VD (n = 99) . | vtD (n = 100) . | ||
|---|---|---|---|---|
| Grades 1-4, % . | Grades 3 or 4, % . | Grades 1-4, % . | Grades 3 or 4, % . | |
| Any adverse event | 99 | 37 | 99 | 43 |
| Hematologic toxicities | ||||
| Anemia | 13 | 3 | 7 | 3 |
| Neutropenia | ||||
| Thrombocytopenia | 19 | 0 | 12 | 3 |
| Infections | 59 | 14 | 58 | 10 |
| Herpes zoster | 7 | 1 | 2 | 0 |
| Thrombosis | 4 | 1 | 7 | 2 |
| Nonhematologic toxicities | ||||
| Cardiac disorders | 9 | 1 | 12 | 2 |
| Fatigue | 53 | 2 | 46 | 6 |
| Gastrointestinal symptoms | 79 | 2 | 89 | 4 |
| Peripheral neuropathy | 70* | 11† | 53* | 3† |
| . | VD (n = 99) . | vtD (n = 100) . | ||
|---|---|---|---|---|
| Grades 1-4, % . | Grades 3 or 4, % . | Grades 1-4, % . | Grades 3 or 4, % . | |
| Any adverse event | 99 | 37 | 99 | 43 |
| Hematologic toxicities | ||||
| Anemia | 13 | 3 | 7 | 3 |
| Neutropenia | ||||
| Thrombocytopenia | 19 | 0 | 12 | 3 |
| Infections | 59 | 14 | 58 | 10 |
| Herpes zoster | 7 | 1 | 2 | 0 |
| Thrombosis | 4 | 1 | 7 | 2 |
| Nonhematologic toxicities | ||||
| Cardiac disorders | 9 | 1 | 12 | 2 |
| Fatigue | 53 | 2 | 46 | 6 |
| Gastrointestinal symptoms | 79 | 2 | 89 | 4 |
| Peripheral neuropathy | 70* | 11† | 53* | 3† |